Compare TG Therapeutics Inc (TGTX) vs Viking Holdings Ltd Ordinary Shares (VIK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Viking Holdings Ltd Ordinary Shares — how do they compare? TG Therapeutics Inc trades at $53.34 (market cap $8.11B), while Viking Holdings Ltd Ordinary Shares trades at $81.62 (market cap $36.29B). The key difference: Viking Holdings Ltd Ordinary Shares is far larger — about 4.5× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Viking Holdings Ltd Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 15 Days and Viking Holdings Ltd Ordinary Shares for 0 Days on average.
| TGTX | VIK | |
|---|---|---|
Market Cap | $8.11B | $36.29B |
Volume | 1,505,658 | 2,522,956 |
Sector | Health | Consumer Cyclical |
52-Week High | $59.06 | $108.26 |
52-Week Low | $26.94 | $57.08 |
Typical Hold Time | 15 Days | 0 Days |
Enterprise Value | $8.31B | $38.67B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $52.95, up 1.46% today, but faces bearish technical signals with recent earnings misses. The company shows strong profitability with 55.22% net margin and 100.28% ROE, while revenue growth continues with BRIUMVI capturing market share. Recent news includes shareholder litigation investigation and buyout speculation.
Despite earnings volatility, TGTX maintains strong fundamentals with analyst consensus at Buy (84.62%) and $80.50 price target. Key risks include ongoing legal scrutiny and execution on BRIUMVI growth, while institutional accumulation signals confidence in long-term prospects.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Viking Holdings Ltd Ordinary Shares
Viking operates river, ocean, and expedition cruises. Its itineraries focus on destination-based travel across Europe, the Americas, and other regions.
Read more on VIK →
